Health1 min read

STAT+: Pharmalittle: We’re reading about a Roche breast cancer pill, obesity drugs in children, and more

By · Via STAT Health · Published by Everything Blog

In short

Roche secured FDA approval for giredestrant, an oral breast cancer medicine projected by analysts to hit multibillion-dollar blockbuster status through potential future indications. Concurrently, data unveiled at ObesityWeek demonstrated that the weight-loss compound semaglutide was effective for patients aged 6 to 11. Over a 68-week trial period, nearly 40% of treated children no longer met the clinical criteria for obesity. However, some physicians remain hesitant about administering these potent weight-loss therapies to such a young demographic.

Key points

  • Giredestrant could achieve multibillion-dollar blockbuster status if Roche secures approv…: Giredestrant could achieve multibillion-dollar blockbuster status if Roche secures approvals across additional breast cancer indications.
  • Semaglutide demonstrated significant efficacy in pediatric patients as young as 6 years o…: Semaglutide demonstrated significant efficacy in pediatric patients as young as 6 years old with severe obesity.
  • Despite positive clinical trial data, some medical professionals are raising concerns reg…: Despite positive clinical trial data, some medical professionals are raising concerns regarding pediatric use of obesity drugs.

Sources checked by our analysis pipeline: 1

Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue skies and comfy breezes are greeting us. As for the official mascots, they are happily snoozing in their respective corners. As for us, we are firing up the trusty kettle for another cup of stimulation. Our choice today is pumpkin spice, which remains a seasonal favorite. Of course, you are invited to join us. For the full experience, we are still hawking replicas — take a look. Meanwhile, here are a few items of interest. As always, do keep in touch. We appreciate feedback, criticism, and tips. …

The U.S. Food and Drug Administration approved a new breast cancer drug from Roche, teeing up the launch of a medicine that the company has said could become its top-selling product ever, STAT says. The approval for the drug, known as giredestrant, was one of the most important regulatory decisions Roche had been awaiting. It gives the company another foothold in breast cancer treatments,…

Health